Investment, Funding & Disinvestments

ATG-201 is designed as a bispecific molecule that binds to both CD3 on T cells and CD19 on B cells, effectively recruiting the body’s own immune system to destroy disease-causing B cells.

The new manufacturing hub represents a core strategic priority for PharmaEssentia as the company works to strengthen its supply chain, increase production flexibility, and diversify its geographic footprint.

This latest facility marks the fourth maternity and children’s ward that the Lordina Foundation has constructed and transferred to local communities and Ghana’s Health Service.

The blueprint prioritizes infrastructure upgrades, expanded clinical services, digital transformation, and financial sustainability for the nation’s only tertiary teaching hospital.

The new comprehensive center will change this reality by providing chemotherapy, radiotherapy, and surgical oncology services under one roof.

This advanced immunotherapy works by modifying a patient’s own immune cells to better identify and destroy cancer cells.

The agreement grants Novo Nordisk licensing rights to select oral drug-delivery technologies from Vivtex.

Saudi Arabia’s pharmaceutical market projects growth to USD15.6 billion by 2030, up from USD11.8 billion in 2024.

Almond Blossoms provides a full range of fertility services, including IVF, ICSI, IUI, egg and sperm freezing, genetic testing, fertility assessments, and individualized reproductive planning.